Aligos Therapeutics (ALGS.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

Sio Capital Management LLC Increased Holdings in Aligos Therapeutics

13:12

Nov10

Aligos Therapeutics Reports Positive Data for Pevifoscorvir Sodium in Chronic Hepatitis B Treatment

13:02

Nov6

Aligos Therapeutics released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 2.017 M and EPS of USD -6.6838

14:30

Aligos Therapeutics released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 741 K (forecast USD 333.33 K), actual EPS USD -3.0413 (forecast USD -1.9)

14:30

Oct30

Aligos Therapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 500K, EPS USD -1.9

00:08

Oct28

Trucchio covers Aligos Therapeutics stock

12:03

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 741 K, Net Income -31.54 M, EPS -3.0413

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 965 K, Net Income -15.86 M, EPS -1.5324

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 311 K, Net Income 43.09 M, EPS -2.1099

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change